Bio-Techne had a net margin of 20.95% and a return on equity of 16.82%. The biotechnology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.21. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.79 and a current ratio of 3.56.īio-Techne ( NASDAQ:TECH – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The stock has a market capitalization of $13.51 billion, a P/E ratio of 62.84, a PEG ratio of 1.57 and a beta of 1.22. The company has a 50 day moving average price of $353.42 and a two-hundred day moving average price of $393.37. has a one year low of $318.07 and a one year high of $543.85. Corporate insiders own 4.10% of the company’s stock. The disclosure for this sale can be found here. Following the transaction, the chief executive officer now owns 198,338 shares in the company, valued at approximately $72,393,370. The shares were sold at an average price of $365.00, for a total transaction of $1,862,960.00. Kummeth sold 5,104 shares of Bio-Techne stock in a transaction on Tuesday, June 7th. The acquisition was disclosed in a filing with the SEC, which is available at this link. Following the acquisition, the director now owns 10,106 shares of the company’s stock, valued at approximately $3,562,870.30. The shares were acquired at an average price of $352.55 per share, for a total transaction of $105,765.00. Baumgartner bought 300 shares of Bio-Techne stock in a transaction that occurred on Tuesday, May 10th. In other Bio-Techne news, Director Robert V. The transaction was disclosed in a filing with the SEC, which is available through this link. Following the purchase, the director now directly owns 10,106 shares of the company’s stock, valued at $3,562,870.30. The stock was bought at an average cost of $352.55 per share, with a total value of $105,765.00. Baumgartner acquired 300 shares of the stock in a transaction dated Tuesday, May 10th. 94.36% of the stock is currently owned by institutional investors and hedge funds. Champlain Investment Partners LLC now owns 423,950 shares of the biotechnology company’s stock worth $219,326,000 after purchasing an additional 31,658 shares during the last quarter. Finally, Champlain Investment Partners LLC raised its position in shares of Bio-Techne by 8.1% during the 4th quarter. now owns 489,904 shares of the biotechnology company’s stock worth $253,447,000 after purchasing an additional 37,150 shares during the last quarter. raised its position in shares of Bio-Techne by 8.2% during the 4th quarter. Marshall Wace LLP now owns 580,835 shares of the biotechnology company’s stock worth $300,491,000 after purchasing an additional 350,215 shares during the last quarter. Marshall Wace LLP raised its position in shares of Bio-Techne by 151.9% during the 4th quarter. Geode Capital Management LLC now owns 762,953 shares of the biotechnology company’s stock valued at $393,692,000 after acquiring an additional 30,699 shares during the period. ![]() Geode Capital Management LLC lifted its position in shares of Bio-Techne by 4.2% during the 4th quarter. State Street Corp now owns 1,608,213 shares of the biotechnology company’s stock valued at $831,993,000 after acquiring an additional 73,760 shares during the period. State Street Corp lifted its position in shares of Bio-Techne by 4.8% during the 4th quarter. Truist Financial Corp’s holdings in Bio-Techne were worth $3,453,000 as of its most recent filing with the Securities & Exchange Commission.Ī number of other hedge funds and other institutional investors also recently modified their holdings of the stock. ![]() The firm owned 7,971 shares of the biotechnology company’s stock after selling 73 shares during the period. ( NASDAQ:TECH – Get Rating) by 0.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. Truist Financial Corp lowered its position in Bio-Techne Co.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |